This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Plaintiffs ask US appeals court to affirm class cert in pharma antitrust litigation

( November 14, 2025, 16:20 GMT | Official Statement) -- MLex Summary: Plaintiffs bringing US antitrust claims against Actavis and Mylan over generic pharmaceuticals told a federal appeals court that the district court correctly applied the appropriate standard to an airtight factual record and certified a classic price-fixing case for a fair and efficient resolution on the merits. They said that the class members will use their own records to show they paid for clobetasol, and Actavis’s own expert agrees the records exist and can be produced, and the class representatives and others have shown it will work.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections